anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This invention discloses a medicine of anti-tumor and anti-plant virus effect---- cyanoacrylate category derivative and its preparing method and biological activity. The following general formula denotes the compound and its preparing method. The definition of R1, R2, R3 in the formula is in instruction book. Materials are carbon bisulfide, cyan acetic ester, dimethyl sulfate, aromatic amine, and sodium cyanide is catalyst, cyanoacrylate category derivative is synthesized by three steps. There is proliferation inhibitory effect of compound b, k to PC3 prostate cancer cell gene stock, and proliferation inhibitory effect of compound i, j to NIN3T3 cell ERK albumen phosphorylation, and good anti-cancer activity is revealed. There is inhibitory activity of compound b, n to tobacco mosaic, and certain anti-plant virus activity is revealed.
Intranasal administration, 24 IU oxytocin. Imaging starting 45min after nasal spray administration.
Active patients (defined as patients seen by an LMC endocrinologist between January 1, 2019 and December 31, 2019) with T2D (Type 2 Diabetes). Among the patients with T2D, those identified with CKD will be included in the renal registry.
PURPOSE:To obtain a thermally and chemically stable novel composite material, by blending an alkoxysilane with a cyclodextrin, adding water to the blend and gelatinizing so that the cyclodextrin is taken in amorphous silane. CONSTITUTION:An alkoxysilane (e.g. tetramethoxysilane, tetrabutoxysilane, etc.) is blended with a cyclodextrin (e.g. beta,gamma,delta-cyclodextrin single substance, etc.) usually in the amount of <=1mol cyclodextrin based on several mol alkoxysilane, 2-30mol based on 1mol alkoxysilane of water is added to the blend and the blend is gelatinized so that amorphous silica is taken in the cyclodextrin. USE:Useful as a catalyst which has high selectivity, is readily separated from a reaction product and can carry out a continuous reaction, as artificial enzyme, adsorption separating agent, long-life capsulating agent for drugs, etc.
Osteoporosis is a multifactorial bone disease characterised by reduced bone mass and increased fracture risk. Family studies have made significant contribution in unravelling the genetics of osteoporosis. Yet, most of the underlying molecular and biological mechanisms remain unknown prompting the need for further studies. This review outlines the proper phenotyping and advanced genetic techniques in the form of high-throughput DNA sequencing used to identify genetic factors underlying monogenic osteoporosis in a family-based setting. The steps related to variant filtering prioritisation and curation are also described. From an evolutionary perspective, deleterious risk variants with higher penetrance tend to be rare as a result of negative selection. High-throughput sequencing (HTS) can identify rare variants with large effect sizes which are likely to be missed by candidate gene analysis or genome-wide association studies (GWAS) wherein common variants with small to moderate effect sizes are identified. We also describe the importance of replicating implicated genes, and possibly variants, identified following HTS to confirm their causality. Replication of the gene in other families, singletons or independent cohorts confirms that the shortlisted genes and/or variants are indeed causal. Furthermore, novel genes and/or variants implicated in monogenic osteoporosis require a thorough validation by means of in vitro and in vivo assessment. Therefore, analyses of families can continue to elucidate the genetic architecture of osteoporosis, paving the way for improved diagnostic and therapeutic strategies.
FIELD: organic chemistry, medicine, pharmacology. SUBSTANCE: invention relates to the research of novel antiviral agents. Invention proposes application of (3-chloro-1-adamantyl)methylketone oxime of the formula:   as an antiviral inhibitor exhibiting high antiviral activity with respect to herpes simplex type 1 and weak activity with respect to influenza virus A. This invention can be used in the development of novel medicinal agents with an antiviral effect. EFFECT: valuable antiviral activity of compound. 2 tbl
Patients who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles and, if exposed, to consult their physician without delay. If exposure to such a person occurs, and the child has not had chicken pox or been properly vaccinated, a physician should be consulted without delay. Patients should be informed of potential worsening of existing tuberculosis, fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex [see Error! Hyperlink reference not valid. (Error! Hyperlink reference not valid.)].
Obesity-induced chronic low-grade inflammation, also known as metaflammation, results from alterations of the immune response in metabolic organs and contributes to the development of fatty liver diseases and type 2 diabetes. The diversity of tissue-resident leukocytes involved in these metabolic dysfunctions warrants an in-depth immunophenotyping in order to elucidate disease etiology. Here, we present a 30-color, full spectrum flow cytometry panel, designed to (i) identify the major innate and adaptive immune cell subsets in murine liver and white adipose tissues and (ii) discriminate various tissue-specific myeloid subsets known to contribute to the development of metabolic dysfunctions. This panel notably allows for distinguishing embryonically-derived liver-resident Kupffer cells from newly recruited monocyte-derived macrophages and KCs. Furthermore, several adipose tissue macrophage (ATM) subsets, including perivascular macrophages, lipid-associated macrophages, and pro-inflammatory CD11c+ ATMs, can also be identified. Finally, the panel includes cell-surface markers that have been associated with metabolic activation of different macrophage and dendritic cell subsets. Altogether, our spectral flow cytometry panel allows for an extensive immunophenotyping of murine metabolic tissues, with a particular focus on metabolically-relevant myeloid cell subsets, and can easily be adjusted to include various new markers if needed.
PROBLEM TO BE SOLVED: To obtain an antioxidant having high anti-oxidizing power, controlling active oxygen and lipid peroxide formed in vivo, having excellent safety by making the antioxidant include an extract of Bursera lancifolia. SOLUTION: This antioxidant contains preferably 0.001-20.0 wt.%, calculated as dried substance based on the total of an extract, of Bursera lancifolia (gomosilla) (a plant of the genus Brucella of the family Burseraceae native to Mexico), preferably an extract from either of leaf or stem of Bursera lancifolia or a mixture of both of the leaf and the stem. Preferably, the amount of an extracting solvent such as water and a water-soluble solvent (e.g. ethanol) used is 100 pts.-wt. based on 5-50 pts.wt. of dried plant or green plant calculated as dried plant.
FASLODEX is metabolized primarily in the liver. 

The pharmacokinetics of fulvestrant were evaluated after a single dose of 100 mg in subjects with mild and moderate hepatic impairment and normal hepatic function (n=7 subjects/group), using a shorter-acting intramuscular injection formulation. Subjects with mild hepatic impairment (Child-Pugh class A) had comparable mean AUC and clearance values to those with normal hepatic function. In subjects with moderate hepatic impairment (Child-Pugh class B), the average AUC of fulvestrant increased by 70% compared to patients with normal hepatic function. AUC was positively correlated with total bilirubin concentration (p=0.012). FASLODEX has not been studied in patients with severe hepatic impairment (Child-Pugh class C). 

A dose of FASLODEX 250 mg is recommended in patients with moderate hepatic impairment (Child-Pugh class B) [see Dosage and Administration (2.2) and Warnings and Precautions (5.2)].
Cerebral ischemia-reperfusion injury (CIRI) leads to malignant brain edema, blood-brain barrier destruction, and neuronal apoptosis. N6-methyladenosine (m6A) RNA modification in CIRI was still limited explored. In this study, MeRIP- and RNA-sequencing were performed of middle cerebral artery occlusion and reperfusion (MCAO/R) rats to find novel potential molecular targets. Transcription factor TFAP2B stood out of which its m6A abundance decreased associated with a marked reduction of its mRNA based on cojoint interactive bioinformatics analysis of the MeRIP- and RNA-sequencing data. It was suggested TFAP2B could have a role in CIRI. Functionally, overexpression of TFAP2B in cultured primary neurons could effectively improve the cell survival and pro-survival autophagy in parallel with reduced cell apoptosis during OGD/R in vitro. Through the RNA-sequencing of TFAP2B overexpressed primary neurons and subsequent validation experiments, it was found that mitophagy receptor BNIP3 was one of the important targets of TFAP2B in OGD/R neurons through which TFAP2B could bind to its promoter region for transcriptional activation of BNIP3, thereby enhancing BNIP3-mediated mitophagy to protect against OGD/R injury of neurons. Lastly, TFAP2B was demonstrated to alleviate the MCAO/R damage to a certain extent in vivo. Although it failed to confirm TFAP2B dysregulation was m6A dependent in current research, this is the first research of TFAP2B in CIRI field with important guiding significance.
A 4-week physical exercise intervention comprised of running with mental association strategies. From 15 to 30 minutes of practice per session, three times/week through workout audio guides.
Nifedipine is an antianginal drug belonging to a class of pharmacological agents, the calcium channel blockers. Nifedipine is 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2, 6-dimethyl -4-(2-nitrophenyl)-, dimethyl ester, C17H18N206 and has the structural formula:

Nifedipine is a yellow crystalline substance, practically insoluble in water but soluble in ethanol. It has a molecular weight of 346.3\. Nifedipine capsules are formulated as soft gelatin capsules for oral administration each containing 10 mg or 20 mg nifedipine.

Inactive Ingredients: Nifedipine capsules for oral administration contain the following inactive ingredients: glycerin, peppermint oil, and polyethylene glycol. The 10 mg capsule shell contains gelatin, glycerin, hypromellose, iron oxide black, iron oxide yellow, propylene glycol, and titanium dioxide. The 20 mg capsule shell contains FD and C red #40, FD and C yellow #6 (sunset yellow), gelatin, glycerin, hypromellose, iron oxide black, iron oxide brown, iron oxide red, propylene glycol, and titanium dioxide.
FIELD: respiratory diseases. SUBSTANCE: to autogenous blood cell paste including all blood cells and obtained from 6-8% whole blood, 30/120 mg of prednisolone and 1- 2 ml of 100 mcg/ml ATP are added. Mixture, prior to be returned to patient, is incubated for 20 min at room temperature. Method reduces time and number of operations as compared to known method, reduces time required for clinical improvement, reduces course and daily prednisolone doze, and essentially reduces maintaining prednisolone doze during posthospital period. EFFECT: enhanced treatment efficiency. 2 cl, 2 tbl, 3 ex
BACKGROUND: Bacterial peritonitis is a common complication of peritoneal dialysis. In the absence of systemic signs of infection, adult guidelines recommend treatment with intraperitoneal vancomycin either as empiric coverage of gram-positive organisms or as targeted therapy. However, there is no guidance on how to administer vancomycin in children on automated peritoneal dialysis.
CASE REPORT: We report vancomycin pharmacokinetics upon intraperitoneal administration for the treatment of a Staphylococcus hominis peritonitis in an 11-year-old patient on automated nocturnal intermittent peritoneal dialysis. While the patient was hospitalized, vancomycin was administered intraperitoneally as a continuous treatment. After hospital discharge, the nocturnal peritoneal dialysis was resumed. In the absence of treatment guidelines, intraperitoneal vancomycin was initially administered empirically only during the nocturnal dialysis exchanges which led to repetitive subtherapeutic vancomycin plasma concentrations and the persistence of S. hominis in dialysate cultures. Based on studies in adults, the dosing strategy was subsequently modified to administer vancomycin at a dosage of 15 mg kg-1 in the dialysate with a 6-h dwell period prior to the nocturnal dialysis thereby allowing to reach optimal peak concentrations. The dosing interval was subsequently individualized using therapeutic drug monitoring to ensure residual vancomycin concentrations > 10 mg L-1 thereby leading to clinical and microbiological recovery.
CONCLUSIONS: This case presents a dosing strategy based on a comprehensive review of the literature and highlights that a sufficient dwell period is critical when treating pediatric patients on automated peritoneal dialysis in order to allow vancomycin distribution and equilibration between the dialysate and the plasma.
PURPOSE: An anti-inflammable composition extracted from Artemisiae iwayomogii herba is provided to drastically reduce the manufacture of nitrogen oxide at macrophage which is processed with LPS. CONSTITUTION: An anti-inflammable composition includes artemisia iwaymogi herba essential oil extracted from the artemisiae iwayomogii herba. The artemisia iwaymogi herba essential oil is obtained by separating and extracting artemisia iwaymogi herba using a distilling device after pulverizing the leaves and flowers of the artemisia iwaymogi herba. The artemisiae iwayomogii herba essential oil extracted from the artemisiae iwayomogii herba includes vulgarone B, camphor and borneol. The anti-inflammable composition includes the vulgarone B as the active ingredient. The vulgarone B is extracted from the artemisia iwaymogi using a steam distillation method.
Caution should be exercised when administering trimethobenzamide hydrochloride capsules to children for the treatment of vomiting. Antiemetics are not recommended for treatment of uncomplicated vomiting in children and their use should be limited to prolonged vomiting of known etiology. There are two principal reasons for caution:

  1. The extrapyramidal symptoms which can occur secondary to trimethobenzamide hydrochloride capsules may be confused with the central nervous system signs of an undiagnosed primary disease responsible for the vomiting, e.g., Reye's syndrome or other encephalopathy.
  2. It has been suspected that drugs with hepatotoxic potential, such as trimethobenzamide hydrochloride capsules, may unfavorably alter the course of Reye's syndrome. Such drugs should therefore be avoided in children whose signs and symptoms (vomiting) could represent Reye's syndrome.



Trimethobenzamide hydrochloride capsules may produce drowsiness. Patients should not operate motor vehicles or other dangerous machinery until their individual responses have been determined.
The invention provides a polymer shown in the formula (I). The invention also provides glucose-sensitive nanogel. The glucose-sensitive nanogel comprises polymer nanogel and glucose oxidase electrostatically compounded with the polymer nanogel. The polymer nanogel is obtained by crosslinking of the polymer shown in the formula (1) and sodium perselenide. The preparation method of the glucose-sensitive nanogel comprises the following steps that the polymer shown in the formula (1) and a sodium perselenide aqueous solution undergo a crosslinking reaction in an organic solvent to produce the polymer nanogel; and the polymer nanogel and glucose oxidase undergo an electrostatic compounding reaction in an aqueous solution to produce the glucose-sensitive nanogel. The glucose-sensitive nanogel has good oxidation sensitivity, biocompatibility and glucose sensitivity, can adjust drug release rate and release behavior by responsing a glucose concentration change when being used as a drug carrier, and can realize fast drug release at a high glucose concentration.
Matching oral solution to Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.
OBJECTIVE: To review the current literature about surgical treatments of pediatric bilateral vocal fold paralysis (PBVFP).
METHODS: A systematic review of the current literature in PubMed, Scopus, and Cochrane Library regarding etiologies and management of PBVFP was performed until November 2023 according to PRISMA statements. Quality assessment was assessed with Methodological Index for Non-Randomized Studies (MINORS) tool.
RESULTS: Of the 211 screened articles, 26 were included accounting for 320 patients. The etiologies included idiopathic (42.2%), congenital (19.7%), neurological (16.9%), or post-surgical (9.5%) pediatric bilateral vocal cord paralysis (PBVCP). Patients were decannulated in 76.7% of cases without laryngeal procedure. Decannulation was achieved in 84.6%, 66.6%, 83.3%, 80.0%, and 62.5% of cases of laterofixation of the vocal fold, cricoid split approaches, partial or total arytenoidectomy, uni- or bilateral transverse cordotomy, and selective laryngeal reinnervation, respectively. Dyspnea/stridor relief, swallowing, or voice quality outcomes were used in some studies, which reported conflicting results. Revision and complications varied between studies, with complications mainly involving edema, granuloma, or aspirations. Revision was required in 6.4%, 12.9%, and 40.0% of cases that underwent laterofixation of the vocal fold, arytenoidectomy, and cricoid split procedures, respectively. There was substantial heterogeneity across studies in inclusion criteria, procedures, and outcomes.
CONCLUSION: The management of PBVFP may involve several temporary or permanent surgical procedures that are associated with overall subjective improvements of symptoms, and laryngeal findings. The retrospective design of studies, the small number of cohorts, the lack of objective outcomes, and the differences between teams regarding procedure timing and features limit drawing reliable conclusions about the superiority of one technique over others.
With emerging antibiotic resistant bacteria it is necessary to try to prevent surgical site infections (SSIs).Not only because of suffering and death but also because of increased costs. For a deep sternal infection the cost can be doubled or even tripled. Sternal wound complications can occur from low numbers up to almost 10%, with different severity, depending on follow up routines In an intraoperative environment causative bacteria often originate from either patient or surgical team. One of many preventing measures is to keep patients and surgical members as sterile as possible when it´s the number of bacteria that overcome the host defense that lead to infection. The most common bacteria causing sternal infection is Coagulase negative staphylococci (CoNS) 46% Staphylococcus aureus, 26% and gram- negative bacteria, 18%. One preventing measure is to wear surgical gloves, and to wear double gloving for easy detection of puncture in outer glove. When using indicator gloves there becomes a dark spot were the hole is which tells you to change the glove. At the glove cuff end it often indicate fluid of some sort by getting dark where the sleeve of the gown meets the glove cuff. One may suspect that the fluid thrives from the hand, and if so does the fluid contains any bacteria from the hands. In open heart surgery surgical team wear their gloves for a long period of time. Research implicates that it occurs some recolonisation of bacteria inside the gloves. Does recolonisation of the hand flora occur after surgical hand washing and is there a bacterial leakage at the glove cuff site? It´s discussed that people that are in contact with hospitals carries more bacteria than others and being admitted to hospital before surgery is a risk factor. It is also known that hospital workers are carriers of more bacteria and possibly also carriers of resistant bacteria. At the other hand hospital workers often wash and disinfect their hands. Are there differences in bacterial recolonization of hand flora between hospital staff at an operating department than people in average society who have little or no contact with hospitals?
This combination product is subject to the provisions of the Controlled Substance Act and has been placed in Schedule III.

Dihydrocodeine can produce drug dependence of the codeine type and therefore has the potential of being abused. Like other opioid analgesics, dihydrocodeine may produce subjected effects other than analgesia (e.g., euphoria, relaxation), which may contribute to abuse by some patients. Psychological dependence, physical dependence, and tolerance may develop upon repeated administration of dihydrocodeine, and it should be prescribed and administered with the same degree of caution appropriate to the use of other oral opioid analgesic medications. Symptoms of dihydrocodeine withdrawal consist of irritability, restlessness, insomnia, diaphoresis, anxiety and palpitations. Prolonged, high intake of caffeine may produce tolerance and habituation. Physical signs of withdrawal, such as headaches, irritation, nervousness, anxiety, and dizziness may occur upon abrupt discontinuation.
Ceftriaxone overdosage has been reported in patients with severe renal impairment. Reactions have included neurological outcomes, including encephalopathy, seizures, myoclonus, and non-convulsive status epilepticus. In the event of overdosage, discontinue Ceftriaxone for Injection therapy and provide general supportive treatment (see DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS).

In the case of overdosage, drug concentration would not be reduced by hemodialysis or peritoneal dialysis. There is no specific antidote. Treatment of overdosage should be symptomatic.
The present disclosure relates to methods of treating chemically loosened hair. The method comprises applying to the chemically loosened hair a neutralizing composition comprising: at least 0.5 wt.% of at least one carboxylic acid, one or more C 2 ‑C 6 A monoalkanolamine, and water. Allowing said neutralizing composition to remain on said hair for a period of time. And alsoTreating the hair with a neutralizing conditioner, said neutralizing conditioner being different from said neutralizing composition. The neutralizing hair conditioner comprises: at least 0.5 wt.% of at least one carboxylic acid, one or more C 2 ‑C 6 A monoalkanolamine, one or more cationic surfactants, and water. Maintaining said neutralized conditioner on said hair for a period of time. After treatment with the neutralizing composition and the neutralizing conditioner, the hair may be further treated with a shampoo, conditioner, conditioning shampoo, or the like, blow dried and/or styled.
The placebo designed for administration in the proposed clinical study consists of a dry powder composed of the same excipients as the active (sodium sulfate, mannitol and polysorbate 80), pre-metered into HPMC capsules at the same 5 mg powder fill weight as the active formulations. Subjects will receive 14 doses administered once daily in the morning.